AvePoint (AVPT) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants James Arestia - VP - Investor RelationsTianyi Jiang - Co-Founder, CEO & DirectorJim Caci - Chief Financial OfficerJoe Vandrick - Associate Director - Equity ResearchJason Ader - Co-Group Head - Technology, Media & CommunicationsNehal Chokshi - Managing DirectorChirag Ved - Vice PresidentCole Erskine - Vice President - Equity ResearchBrett Knoblauch - Managing Director Operator Good day, and welcome to the Airfind Inc. First ...

Financial Data and Key Metrics Changes - Revenue for Q1 was $598 million, reflecting a slight decline of 0.8% year-over-year on a constant currency basis [7][21] - Non-GAAP EPS increased by 9% to $0.68 compared to the prior year [8][22] - Free cash flow reached a record $141 million, up 493% year-over-year [9][36] - GAAP net income was $75.5 million, translating to fully diluted GAAP earnings of $0.54 per share [22] Business Line Data and Key Metrics Changes - U.S. Spine revenue grew by 2% in Q1, driven by strong product portfolio performance [10][23] - Enabling Technologies revenue decreased by 31% to $22 million, impacted by market uncertainty [14][21] - International Spine implant business grew by 1% on a constant currency basis, affected by distributor order timing [15][29] - Combined trauma and NSO business declined by 8%, although core trauma grew by 34% [16] Market Data and Key Metrics Changes - U.S. Spine business showed above-market growth exiting April, with positive momentum expected in Q2 [11][12] - International revenue was $114.3 million, down 7.7% as reported, primarily due to supply chain disruptions [29] - The overall market for musculoskeletal products is expected to recover as supply chain issues are resolved [36] Company Strategy and Development Direction - The company aims to focus on sustained profitable growth and operational excellence while integrating the Nevro acquisition [10][18] - The acquisition of Nevro is seen as a strategic move to expand into the musculoskeletal market, adding a $3 billion market space [16][17] - The company plans to leverage its financial strength to accelerate investments in neuromodulation and improve cash flow [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in recovering from Q1 challenges, citing improvements in U.S. Spine and supply chain remediation [46][48] - The company anticipates a strong Q2 performance, with positive trends in sales and order fulfillment [40][41] - Management acknowledged the impact of market uncertainty but remains optimistic about long-term growth potential [76][78] Other Important Information - The company returned to debt-free status after paying off nearly $900 million in debt from the NuVasive merger [9][33] - The company has completed its share repurchase program, buying back over 20% of the dilution from the merger [34][35] - The company is actively addressing tariff impacts through cost action offsets and vendor negotiations [38][116] Q&A Session Summary Question: Confidence in recovery from Q1 performance - Management noted that supply chain disruptions and timing of distributor orders were temporary issues, with confidence in a recovery in Q2 [46][48] Question: Synergies from Nevro acquisition - Focus will be on reducing operational expenses and improving gross margins over time [50][51] Question: Impact of competitors on sales cycles - No significant impact from competitors was noted, although financing options are being explored [56] Question: Organic growth guidance - Organic growth components remain consistent, with expectations to recover lost sales from Q1 [72][82] Question: FDA warning letter status - Progress has been made, and management is awaiting inspection to resolve the issue [98] Question: Future M&A plans - Near-term focus will be on integrating Nevro and NuVasive before pursuing further acquisitions [99] Question: Market growth and procedural health - Management indicated some slowdown in market growth but emphasized the importance of clearing back orders and launching new products [101][102]

OmniAb (OABI) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Kurt Gustafson - CFOMatthew Foehr - President & CEOBob Chen - VP of Discovery SystemsMichael Sonntag - Life Science Tools & DiagnosticsAlex Nackenoff - Biotech Equity Research AssociateJacqueline Kisa - Equity Research AssociateNone - Executive Conference Call Participants Joseph Pantginis - MD & Senior Healthcare AnalystNone - AnalystTollef Kohrman - Associate Analyst Operator Good afternoon, and welcome to OmniAb, Inc. First ...

Profound Medical (PROF) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Stephen Kilmer - Investor RelationsRashed Dewan - CFOMathieu Burtnyk - PresidentTom Tamberrino - Chief Commercial OfficerArun Menawat - Chairman & CEOBen Haynor - Managing DirectorJohn McAulay - AVPScott McAuley - Head of Research Conference Call Participants Michael Freeman - Equity Research Analyst - Healthcare Operator Good day, and thank you for standing by. Welcome to the Profound Medical First Quarter twenty tw ...

Financial Data and Key Metrics Changes - The company recognized $400,000 in revenue during Q1 2025, down from $600,000 in Q1 2024, with revenue being non-cash based on amortization of payments from a licensing arrangement [40] - Research and development (R&D) expenses increased by 43% to $76.2 million in Q1 2025 compared to the same period in 2024, primarily due to additional personnel and higher manufacturing costs [40] - Selling, general, and administrative (SG&A) expenses rose by 71% to $35.5 million in Q1 2025, driven by growth to support ongoing programs and the planned commercial launch of paltusotine [41] - Cash used in operations for Q1 2025 was $88.5 million, compared to $52.9 million in Q1 2024, with expectations of cash used in operations for 2025 between $340 million and $380 million [42] - The company ended Q1 2025 with approximately $1.3 billion in cash, cash equivalents, and investments, expected to fund operations into 2029 [42] Business Line Data and Key Metrics Changes - The company is focused on the anticipated commercial launch of paltusotine, which is expected to significantly improve treatment for patients with acromegaly [8][10] - The pipeline includes two late-stage candidates and three additional candidates in preclinical studies, indicating a robust development strategy [8] Market Data and Key Metrics Changes - The company is preparing for the launch of paltusotine in the U.S. and has engaged with payers, receiving positive feedback regarding the product's value proposition [18][23] - The anticipated launch strategy includes educating healthcare professionals and patients, with a focus on addressing the unmet needs in acromegaly treatment [12][16] Company Strategy and Development Direction - The company aims to become a fully integrated global commercial organization, with a strong commitment to patient care and scientific innovation [8] - The strategic focus includes advancing a robust pipeline while preparing for the commercial launch of paltusotine, which is seen as a pivotal milestone [10][24] - The company is also exploring opportunities in the CAH (congenital adrenal hyperplasia) market with the development of adomelna [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the regulatory engagement with the FDA and the progress of clinical development activities [10][24] - The company remains optimistic about the potential uptake of paltusotine during the early launch phase, anticipating major interest from healthcare providers and patients [23] Other Important Information - The company has welcomed a new CFO, Toby Schulke, who brings extensive experience in transitioning R&D-focused companies into commercial organizations [9] - The company has launched the Kineticare patient support service platform to assist patients throughout their treatment journey [16][17] Q&A Session Summary Question: Can you discuss the powering of your primary endpoint and any data from cohort four? - Management indicated that the study is highly powered to detect significant differences between treatment and placebo groups, and cohort four is currently enrolling with no data available yet [46][48] Question: Is the CALM CAH study design approved by the FDA for registration? - The protocol was developed with input from the FDA, and the company expects to discuss the indication statement based on the data collected [51][54] Question: What is the rationale for testing the primary endpoint at a single time point? - Management explained that responder analyses are typically conducted at single points in time due to variability in biochemical markers, and they are confident in achieving the endpoint [57][58] Question: What is the rationale for morning versus evening dosing in cohort four? - The company aims to explore the convenience of morning dosing while considering the diurnal rhythm of CAH patients [61][62] Question: How is the launch strategy different in Europe compared to the U.S.? - The European markets are more concentrated in terms of patient populations, and the company is preparing for a launch in Germany while considering Brazil for expansion [64][68]

HireQuest (HQI) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Jennifer Belodeau - Vice PresidentRick Hermanns - President and Chief Executive OfficerSteve Crane - CFOKevin Steinke - Managing Director Operator Good afternoon, everyone, and thank you for participating in today's conference call to discuss HireQuest's financial results for the First Quarter ended 03/31/2025. At this time, all participants are in a listen only mode. A question and answer session will follow the formal pres ...

TELA Bio (TELA) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Louisa Smith - PrincipalAntony Koblish - Co-Founder, CEO & PresidentRoberto Cuca - CFO & COOMichaela Smith - Equity Research Associate Conference Call Participants Frank Takkinen - Senior Research AnalystMichael Sarcone - AnalystDavid Turkaly - Research Analyst Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio First Quarter twenty twenty five Earnings Conference Call. At this time, all participants a ...

Aqua Metals (AQMS) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Bob Meyers - Investor RelationsSteve Cotton - CEO, President & DirectorJudd Merrill - CFOEric West - CFO Conference Call Participants Mickey Legg - Equity Research Analyst Bob Meyers Any forward looking statements. The company does not undertake and specifically disclaims any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. As a r ...

BILL Holdings (BILL) Q3 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Karen Sansot - VP of Investor RelationsRené Lacerte - Founder, CEO & Chairperson of the BoardJohn Rettig - President & CFOIan Black - Equity Research AssociateDarrin Peller - Managing DirectorAlex Markgraff - Vice President - Equity ResearchAdib Choudhury - Senior Equity Research Associate Conference Call Participants Tien-tsin Huang - Senior AnalystKen Suchoski - Equity Research AnalystChris Quintero - AnalystAndrew Sc ...

Skye Bioscience (SKYE) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Bernie Hertel - Head IR & CommunicationsPunit Dhillon - President, CEO, Secretary & DirectorChris Twitty - Chief Scientific OfficerKaitlyn Arsenault - Chief Financial OfficerPuneet Arora - Chief Medical Officer Conference Call Participants None - AnalystJay Olson - Managing Director & Senior Analyst - BiotechnologyAlbert Lowe - Senior Research AnalystEdward Tenthoff - Sr. Research AnalystKristen Kluska - AnalystAndy H ...